Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Add-on acarbose effects on inflammation and gut microbiota in type 2 diabetes
ChiCTR-TRC-11001753Phase 4Completed
- Sponsor
- The Second Affiliated Hospital of Dalian Medical University
- Start
- Aug 2008
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of acarbose in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by The Second Affiliated Hospital of Dalian Medical University. Primary endpoint: fasting capillary glucose. Started Aug 2008; status: completed.
02
Drugs
acarbose
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR-TRC-11001753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-11001753.